# US 2026/0062418 A1 · Solid forms of posiphen d-tartrate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062418 A1
- Document ID: US20260062418A1
- Status: Published application
- Kind: A1
- Application number: 19/381,358
- Filed: 2025-11-06
- Published: 2026-03-05
- Earliest claimed: 2023-06-21
- Assignees: Annovis Bio, Inc.
- Applicants: Annovis Bio, Inc.
- Inventors: Maria Maccecchini; Michael A. Christie; Vinu V. Panikkattu; Christopher Scott Seadeek
- Web page: https://patentgrep.com/patent/US20260062418A1

## CPC

- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 487/04: Ortho-condensed systems
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- C07C 59/255: Tartaric acid
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Solid forms of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate, including crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate (posiphen D-tartrate Form A), crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B), crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate Form A having the peak of Pattern C (posiphen D-tartrate Form A+Pattern C), and amorphous (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate, are disclosed. Pharmaceutical compositions comprising posiphen D-tartrate Form A, posiphen D-tartrate Form B, posiphen D-tartrate Form A having the peaks of Pattern C, and amorphous posiphen D-tartrate, and methods of treating various conditions by administering these solid forms, are also disclosed.

## Claims

### Claim 1

A solid form of crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B).

### Claim 2

A solid form of crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B), characterized by an X-ray powder diffraction pattern having characteristic peaks at 5.16, 8.56, 10.3, 11.24, 13.14, 13.48, 14.66, 15.24, 15.44, 15.76, 16.18, 16.54, 17.48, 17.94, 18.08, 19.72, 20.62, 20.76, 21.22, 21.5, 22.2, 22.54, 23.46, 24.4, 24.72, 26.4, 26.86, 27.14, 27.48, 27.7, 28.52, 28.74, 29.14, 29.96, 30.68, 31.14, 32.3, 33.26, 35.44, 37.24, and 37.74 in 2θ.

### Claim 3

A solid form of crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B), characterized by an X-ray powder diffraction pattern having the following characteristic peaks, relative intensities, and d-spacing values:
Diffraction
Relative
d-spacing
Angle 2θ
Intensity %
Value (Å)
5.16
100
17.13
8.56
10
10.33
10.3
13
8.59
11.24
14
7.87
13.14
17
6.74
13.48
6
6.57
14.66
11
6.04
15.24
28
5.81
15.44
12
5.74
15.76
14
5.62
16.18
29
5.48
16.54
9
5.36
17.48
24
5.07
17.94
9
4.94
18.08
63
4.91
19.72
51
4.50
20.62
19
4.31
20.76
9
4.28
21.22
9
4.19
21.5
17
4.13
22.2
8
4.00
22.54
19
3.94
23.46
17
3.79
24.4
9
3.65
24.72
5
3.60
26.4
15
3.38
26.86
10
3.32
27.14
10
3.29
27.48
6
3.25
27.7
15
3.22
28.52
10
3.13
28.74
5
3.11
29.14
6
3.06
29.96
14
2.98
30.68
6
2.91
31.14
9
2.87
32.3
5
2.77
33.26
5
2.69
35.44
7
2.53
37.24
5
2.41
37.74
5
2.38.

### Claim 4 (depends on 1)

The solid form of crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate of claim 1, wherein the solid form has the following unit cell information:
Space group
P212121
Cell Volume (Å3)
2677.8
a (Å)
7.1291832
α (°)
90
b (Å)
10.8795518
β (°)
90
c (Å)
34.5244343
γ (°)
90.
dsamp (mm)
−0.147
Rwp
9.2%.

### Claim 5 (depends on 1)

The posiphen D-tartrate Form B of claim 1, having a purity of greater than 99.5% as determined by HPLC.

### Claim 6 (depends on 2)

The posiphen D-tartrate Form B of claim 2, having a purity of greater than 99.5% as determined by HPLC.

### Claim 7 (depends on 3)

The posiphen D-tartrate Form B of claim 3, having a purity of greater than 99.5% as determined by HPLC.

### Claim 8 (depends on 1)

A method of preparing the solid form of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B) of claim 1, comprising preparing crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate (posiphen D-tartrate Form A) and converting the posiphen D-tartrate Form A to crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B), wherein the posiphen D-tartrate Form B has a purity of greater than 99.5% as determined by HPLC.

### Claim 9 (depends on 2)

A method of preparing the solid form of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B) of claim 2, comprising preparing crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate (posiphen D-tartrate Form A) and converting the posiphen D-tartrate Form A to crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B), wherein the posiphen D-tartrate Form B has a purity of greater than 99.5% as determined by HPLC.

### Claim 10 (depends on 3)

A method of preparing the solid form of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B) of claim 3, comprising preparing crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate (posiphen D-tartrate Form A) and converting the posiphen D-tartrate Form A to crystalline (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B), wherein the posiphen D-tartrate Form B has a purity of greater than 99.5% as determined by HPLC.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the solid form of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B) of claim 1, and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 2)

A pharmaceutical composition comprising the solid form of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B) of claim 2, and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 3)

A pharmaceutical composition comprising the solid form of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B) of claim 3, and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 11)

A method of treating a neurological disorder in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 11;
wherein the neurological disorder comprises:
a chronic neurodegeneration, comprising Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy, tauopathies, Parkinson's and alpha-synucleopathies, prion disease, transmissible spongiform encephalopathies (TSE), Down Syndrome, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, or other dementias and neurodegenerative disorders which present as misfolding, aggregation and accumulation of proteins in the brain, resulting in axonal transport impairment, inflammation, and eventual cell death; or
an acute neurodegeneration, wherein the acute neurodegeneration comprises traumatic brain injury, stroke, acute brain injury induced by brain ischemia, acute brain injury induced by insufficient oxygen supply to the brain, acute brain injury induced by anoxia or hypoxia, micro infarcts, acute brain injury induced by concussion, post-operative cognitive decline resulting from anesthesia or surgery-induced inflammation, acute brain injury induced by drowning, acute brain injury associated with whip lash, acute brain injury associated with bicycle crashes, acute brain injury associated with automobile accidents, shaken baby syndrome, acute brain injury induced by falling, acute brain injury associated with physical impact of the head, or acute angle-closure glaucoma; or
a neuropsychiatric indication, wherein the neuropsychiatric indication comprises depression, schizophrenia, dementia, Alzheimer's disease, anxiety, or substance abuse disorder; or
a mental illness comprising autism, attention deficit-hyperactivity disorder, bipolar disorder, depression and major depressive disorder, behavioral problems, posttraumatic stress disorder or schizophrenia.

### Claim 15 (depends on 14)

The method of claim 14, wherein the neurological disorder is a chronic neurodegeneration.

### Claim 16 (depends on 15)

The method of claim 15, wherein the chronic neurodegeneration comprises Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy, tauopathies, Parkinson's and alpha-synucleopathies, prion disease, transmissible spongiform encephalopathies (TSE), Down Syndrome, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, or other dementias and neurodegenerative disorders which present as misfolding, aggregation and accumulation of proteins in the brain, resulting in axonal transport impairment, inflammation, and eventual cell death.

### Claim 17 (depends on 14)

The method of claim 14, wherein the neurological disorder is an acute neurodegeneration.

### Claim 18 (depends on 17)

The method of claim 17, wherein the acute neurodegeneration comprises traumatic brain injury, stroke, acute brain injury induced by brain ischemia, acute brain injury induced by insufficient oxygen supply to the brain, acute brain injury induced by anoxia or hypoxia, micro infarcts, acute brain injury induced by concussion, post-operative cognitive decline resulting from anesthesia or surgery-induced inflammation, acute brain injury induced by drowning, acute brain injury associated with whip lash, acute brain injury associated with bicycle crashes, acute brain injury associated with automobile accidents, shaken baby syndrome, acute brain injury induced by falling, acute brain injury associated with physical impact of the head, or acute angle-closure glaucoma.

### Claim 19 (depends on 14)

The method of claim 14, wherein the neurological disorder is a neuropsychiatric indication.

### Claim 20 (depends on 19)

The method of claim 19, wherein the neuropsychiatric indication comprises depression, schizophrenia, dementia, Alzheimer's disease, anxiety, or substance abuse disorder.

### Claim 21 (depends on 14)

The method of claim 14, wherein the neurological disorder is a mental illness.

### Claim 22 (depends on 21)

The method of claim 21, wherein the mental illness comprises autism, attention deficit-hyperactivity disorder, bipolar disorder, depression and major depressive disorder, behavioral problems, posttraumatic stress disorder or schizophrenia.

### Claim 23 (depends on 14)

The method of claim 14, wherein the dosage of posiphen D-tartrate Form B is from about 0.1 mg/kg to about 100 mg/kg of body weight; or wherein the dosage of posiphen D-tartrate Form B is from about 1 mg/kg to about 20 mg/kg of body weight.

### Claim 24 (depends on 14)

The method of claim 14, wherein the pharmaceutical composition is administered daily to the subject; or wherein the pharmaceutical composition is administered once daily to the subject.

### Claim 25 (depends on 14)

The method of claim 14, wherein the subject is a human.

### Claim 26 (depends on 14)

The method of claim 14, wherein the administrating is oral administration.

### Claim 27 (depends on 14)

The method of claim 14, wherein the neurological disorder is Alzheimer's disease.

### Claim 28 (depends on 12)

A method of treating Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 12.

### Claim 29 (depends on 13)

A method of treating Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 13.

### Claim 30

A method of treating Alzheimer's disease in a subject in need thereof, comprising orally administering to the subject an effective amount of a pharmaceutical composition comprising a solid form of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate (posiphen D-tartrate Form B) and a pharmaceutically acceptable carrier;
wherein the solid form of (3aR)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a-hexahydropyrrolo (2, 3-b) indol-5-yl phenyl-carbamate tartrate dihydrate:
a) is characterized by an X-ray powder diffraction pattern having characteristic peaks at 5.16, 8.56, 10.3, 11.24, 13.14, 13.48, 14.66, 15.24, 15.44, 15.76, 16.18, 16.54, 17.48, 17.94, 18.08, 19.72, 20.62, 20.76, 21.22, 21.5, 22.2, 22.54, 23.46, 24.4, 24.72, 26.4, 26.86, 27.14, 27.48, 27.7, 28.52, 28.74, 29.14, 29.96, 30.68, 31.14, 32.3, 33.26, 35.44, 37.24, and 37.74 in 2θ; or
b) is characterized by an X-ray powder diffraction pattern having the following characteristic peaks, relative intensities, and d-spacing values:
Diffraction
Relative
d-spacing
Angle 2θ
Intensity %
Value (Å)
5.16
100
17.13
8.56
10
10.33
10.3
13
8.59
11.24
14
7.87
13.14
17
6.74
13.48
6
6.57
14.66
11
6.04
15.24
28
5.81
15.44
12
5.74
15.76
14
5.62
16.18
29
5.48
16.54
9
5.36
17.48
24
5.07
17.94
9
4.94
18.08
63
4.91
19.72
51
4.50
20.62
19
4.31
20.76
9
4.28
21.22
9
4.19
21.5
17
4.13
22.2
8
4.00
22.54
19
3.94
23.46
17
3.79
24.4
9
3.65
24.72
5
3.60
26.4
15
3.38
26.86
10
3.32
27.14
10
3.29
27.48
6
3.25
27.7
15
3.22
28.52
10
3.13
28.74
5
3.11
29.14
6
3.06
29.96
14
2.98
30.68
6
2.91
31.14
9
2.87
32.3
5
2.77
33.26
5
2.69
35.44
7
2.53
37.24
5
2.41
37.74
5
2.38.
